Every 8-K that TruBridge Inc (TBRG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TBRG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TBRG filings page.
TruBridge, Inc. has been acquired and taken private by Inventurus Knowledge Solutions, Inc. (IKS Health). On July 9, 2026, Merger Sub was merged into TruBridge, which now operates as a wholly owned subsidiary of the buyer.
At the merger effective time, each share of TruBridge common stock (other than excluded and appraisal shares) was converted into the right to receive $26.25 per share in cash, without interest. In connection with closing, TruBridge repaid in full and terminated its existing Amended and Restated Credit Agreement, including all related guarantees and liens.
The acquirer funded the deal through $635.0 million of senior secured credit facilities. TruBridge requested Nasdaq delist its common stock, which ceased trading before the July 9, 2026 market open, and the company plans to deregister the shares and suspend its SEC reporting obligations following effectiveness of a Form 25 and subsequent Form 15 filing.
TruBridge, Inc. stockholders approved its planned merger with Inventurus Knowledge Solutions, Inc. at a special meeting held July 7, 2026. The merger will combine TruBridge with IKS Next Horizon, Inc., making TruBridge a wholly owned subsidiary of Inventurus Knowledge Solutions, Inc.
Of 14,999,136 shares outstanding as of the record date, 11,334,144 shares (about 75.6%) were represented, providing a quorum. The merger proposal passed with 11,305,399 votes for, 8,818 against and 19,927 abstaining. Stockholders also approved, on a non-binding advisory basis, merger-related compensation for named executive officers.
The company expects the merger to close on July 9, 2026, subject to remaining customary conditions. After closing, TruBridge common stock is expected to be delisted from the Nasdaq Global Select Market, and no stockholders exercised appraisal rights in connection with the transaction.
TruBridge, Inc. reported that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its planned merger with Inventurus Knowledge Solutions’ affiliate expired on June 22, 2026, allowing the transaction to move past this key U.S. antitrust review step.
The company still must satisfy other closing conditions in the Merger Agreement, including approval of the deal by holders of a majority of TruBridge common shares entitled to vote. TruBridge has mailed a definitive proxy statement to stockholders and urges them to review it before voting on the proposed merger.
TruBridge, Inc. reported first-quarter 2026 results and highlighted its pending cash acquisition by IKS Health. Under the definitive agreement, TruBridge shareholders will receive $26.25 in cash per common share, with closing expected in the third calendar quarter of 2026, subject to shareholder and regulatory approvals.
For the quarter ended March 31, 2026, TruBridge generated $86.3 million in revenue versus $87.2 million a year earlier. GAAP net income was $0.5 million, or $0.03 per diluted share, compared with $0.5 million and the same per-share result in 2025. Non-GAAP net income rose to $8.5 million, driving non-GAAP EPS of $0.59 versus $0.36.
Adjusted EBITDA was $16.5 million compared with $18.2 million a year ago. Cash and cash equivalents increased to $35.4 million from $24.9 million at year-end 2025, supported by $15.5 million of net cash provided by operating activities. Total bookings on an annual contract value basis were $17.7 million, slightly above the prior-year quarter.
TruBridge, Inc. agreed to be acquired by Inventurus Knowledge Solutions, Inc. through a cash merger at $26.25 per share, with TruBridge becoming a wholly owned subsidiary of IKS’s U.S. unit.
The deal requires approval by TruBridge stockholders, specified Indian shareholder approvals for IKS Health, expiration of Hart-Scott-Rodino antitrust waiting periods, and absence of a Company Material Adverse Effect. Voting and support agreements cover approximately 27% of TruBridge common stock, while specified TopCo shareholders holding about 62% of TopCo equity agreed to support required Indian approvals. The merger includes a $12,292,875 termination fee payable by TruBridge in certain circumstances and a $24,585,750 reverse termination fee payable by Parent if key conditions, including TopCo approval or Parent closing obligations, are not met.
TruBridge, Inc. reported fourth quarter and full year 2025 results and outlined a broad strategic review. For 2025, revenue was $346.8 million versus $342.2 million in 2024, while net income swung to a $4.4 million profit from a $20.9 million loss.
Adjusted EBITDA rose to $68.7 million with a 19.8% margin, up from 16.3%, reflecting cost controls and offshoring initiatives. Cash grew to $24.9 million with total assets of $402.5 million and stockholders’ equity of $178.0 million. Total 2025 bookings were $82.9 million, with Annual Contract Value bookings of $70.9 million.
The company is reviewing alternatives to maximize shareholder value, including potential asset sales, combinations, repurchases, or organic investments, while cautioning that no transaction is assured. Management also identified and revised immaterial errors in prior-period financials, mainly around revenue timing and capitalized software costs, after concluding they were not material to 2023–2025 results.
TruBridge, Inc. entered into a cooperation agreement with Pinetree Capital Ltd. and L6 Holdings Inc., under which the company will expand its board by one seat and appoint Damien Leonard as a director, effective January 12, 2026, and nominate him at the 2026 annual meeting. The company confirmed that director David A. Dye will not stand for reelection at that meeting, and two additional long‑serving directors will retire at the 2026 annual meeting, with another long‑serving director retiring at the 2027 annual meeting. After the 2026 annual meeting, the board will be capped at seven directors without Pinetree’s consent, and the board will give due and serious consideration to a Pinetree‑recommended candidate in connection with the 2027 transition.
During the term of the agreement, Pinetree will generally vote its TruBridge shares in line with the board’s recommendations, subject to specified exceptions, and is subject to standstill and non‑disparagement provisions, including a cap on beneficial ownership at 20% of outstanding common stock. Mr. Leonard is expected to join the compensation committee, has waived his director fees, and there are no disclosable related‑party transactions or family relationships tied to his appointment.
TruBridge, Inc. filed a current report to let investors know it has released financial information for the third quarter ended September 30, 2025. The company states that on November 6, 2025 it issued a press release covering its results of operations and financial condition for this period.
The press release is included as Exhibit 99.1 and is described as being furnished to, but not filed with, the Securities and Exchange Commission. TruBridge’s common stock, with a par value of $0.001 per share, trades on The NASDAQ Stock Market LLC under the symbol TBRG.
TruBridge, Inc. announced that Chief Sales Officer Dawn M. Severance will leave the company effective October 31, 2025, after senior management decided to eliminate the Chief Sales Officer position. The company states her departure is not due to any disagreement over operations, policies, or practices.
Under her June 20, 2023 Executive Severance Agreement, she will receive twelve months of installment payments equal in total to her 2025 base salary plus target bonus, up to twelve months of medical and dental continuation reimbursements, continued vesting of unvested restricted stock while she remains under non-competition and non-solicitation covenants, and pro rata cash incentive and performance share awards based on actual performance over the relevant periods. She will also sign a General Release of Claims effective October 31, 2025. The company separately announced the hiring of Michael Daughton as Chief Business Officer, effective October 6, 2025.